Liver Cirhhosis. Chronic hepatic failure
Conditions
Interventions
Intervention 1: Atorvastatin, tab 20 mg oral, once daily, for 6 months along with ?Asprin, tab 80 mg Oral, once daily, for six months. Intervention 2: Atorvastatin, tab 20 mg, oral, once daily, for 6
Treatment - Drugs
Placebo
Atorvastatin, tab 20 mg oral, once daily, for 6 months along with ?Asprin, tab 80 mg Oral, once daily, for six months
Atorvastatin, tab 20 mg, oral, once daily, for 6 months along with placebo (of Aspirin), Oral, once daily, for 6 months
Sponsors
Office of Research & Technology, Qom University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients with compensated cryptogenic cirrhosis; living in Qom; Age of 18 to 75 years; patient without another type of cirrhosis; who have not been treated with statins; patients with serum LDL>70; Patients with PLT>50000 Exclusion criteria: Increased liver enzymes more than three times, three months after treatment; Lack of cooperation in the proper use of drugs; Statin-induced myopathy; use of Fibrates, Erythromycin, and other drugs that suppressed metabolism of p450 liver enzyme
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sevirity of fibrosis. Timepoint: six months after begining intervention. Method of measurement: kpa with fibroscan.;Liver function. Timepoint: six months after begining intervention. Method of measurement: child score. | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver enzymes levels. Timepoint: six month after begining of intervention. Method of measurement: IU/L. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMansoureh Molaei
Qom University of Medical Sciences
Outcome results
None listed